Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This review discusses the regulations and clinical safety aspects of hair care cosmetics, highlighting the FDA's recommendation to evaluate these products for allergic reactions, avoid contamination, and include antimicrobial agents to ensure consumer safety, with ongoing monitoring through consumer feedback.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

Finasteride toxicity information is limited, poor quality, and biased.

This review discusses the potential mechanisms and evidence supporting low-level laser therapy for stimulating hair growth in men and women, while noting its safety and effectiveness but needing further study on specific parameters.

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

This study reports that FDA-approved scalp cooling caps, like DigniCap and Paxman, can help 50-66% of breast cancer patients retain at least 50% of their hair during chemotherapy, with specific recommendations and limitations discussed for different patient groups.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This commentary explores the marketing of unproven and unlicensed adipose-derived stem cell treatments in US clinics, highlighting concerns about patient safety and regulatory challenges.

This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

This study found that the current approval processes by major regulators like the EMA and FDA for HPV vaccines may rely on only half of the available trial data.

This review discusses educational activities for dermatologists on diagnosing and managing different types of hair loss and reports no new clinical results; it emphasizes improving clinical skills for alopecia treatment.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This review discusses biotin supplementation for dermatological conditions and highlights the lack of strong evidence supporting its efficacy, as well as the potential for laboratory testing interference.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This systematic review found that both oral and topical minoxidil have similar efficacy in improving hair density and terminal hair density among patients with androgenetic alopecia, suggesting that oral minoxidil may be a viable second-line or adjunct treatment option.

This abstract describes the use of lasers in hair transplantation for creating recipient sites and enhancing hair growth but reports no new findings.

This review discusses the factors affecting laser hair removal results and adverse events, emphasizing the need for more research to determine optimal treatment parameters; it reports no new clinical findings.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This study reports that saw palmetto may effectively treat benign prostatic hyperplasia symptoms and potentially stimulate hair growth with generally mild side effects.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.